This is exacerbated by the development and confirmed spread of resistance to artemisinin drugs, the principal component of the first-line malaria treatments that are currently used worldwide. PMI-supported activities include both regional and cross-cutting activities, such as surveillance for antimalarial drug resistance, antimalarial drug quality monitoring, and regional capacity building, as well as targeted malaria prevention and control activities. Hydroxychloroquine natural killer cells Chloroquine autophagy neurons Within SE Asia, the Greater Mekong Subregion GMS has been one of the most dangerous foci of malaria. The GMS is comprised of Cambodia, China Yunnan province, Lao PDR, Myanmar Burma, Thailand, and Vietnam, which vary in political structure, socio-economic and financial resources, public health system, and disease ecology. The Greater Mekong Subregion economic cooperation program identifies and implements high-priority projects in the six countries that share the Mekong river. Sep 12, 2019 Intensive malaria transmission along international borders is a significant impediment to malaria elimination in the Greater Mekong Subregion GMS of Southeast Asia. Passive case detection PCD was used to study the dynamics and trends of malaria transmission at the China–Myanmar border to provide epidemiologic information for improved malaria control. PCD was conducted in one hospital and. Each plan reviews the current status of malaria control and prevention policies and interventions, identifies challenges and unmet needs to achieve PMI goals, and provides a description of planned PMI-funded activities. View more » The Malaria Operational Plans below are detailed 1-year implementation plans for PMI focus countries. Greater mekong subregion chloroquine resistance Greater Mekong Subregion multicountry grant to eliminate., Greater Mekong Subregion GMS Chloroquine alcoholChloroquine adme The emergence in 2009 of Plasmodium falciparum parasites resistant to the primary therapies currently in use artemisinin-based combination therapy, ACT in Southeast Asia threatens to set back decades of global progress in malaria control and elimination. Progress to date through multiple sets of initiatives and partners to contain or eliminate these parasites has been hampered due to a wide. Eliminate now seven critical actions required to accelerate.. Increasing trends of malaria in a border area of the Greater.. Malaria Elimination in the Greater Mekong Subregion.. Across the Greater Mekong subregion and their susceptibility to alternative drug combinations, and discussed the major risks and uncertainties in the longer term. The results of this study are reminiscent of the evolution of chloroquine resistance, wherein multiple P falciparum chloroquine resistance transporter Pfcrt Studies conducted in some parts of Africa and in the Greater Mekong subregion indicate high ef cacy. More studies are needed to con rm its current ef cacy in endemic countries. Chloroquine remains the treatment of choice for P. vivax malaria in areas where it remains effective. The Greater Mekong Subregion GMS, which comprises Cambodia, the Lao People’s Democratic Republic, Myanmar, Thailand, Viet Nam and Yunnan Province of China, has long been the epicentre of antimalarial drug resistance. 4 The first cases of artemisinin resistance were reported in Cambodia in 2008. 5 Since then, artemisinin resistance has been.